Drug Patents owned by Xspire Pharma

1. Drug name - ZONTIVITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7304078 XSPIRE PHARMA Thrombin receptor antagonists
Apr, 2024

(1 year, 6 months from now)

US7713999 XSPIRE PHARMA Thrombin receptor antagonists
May, 2024

(1 year, 7 months from now)

CN1878552A XSPIRE PHARMA Methods Of Use Of A Thrombin Receptor Antagonist
Jan, 2010

(12 years ago)

CN101128457A XSPIRE PHARMA Thrombin Receptor Antagonist
May, 2014

(8 years ago)

CN1203070C XSPIRE PHARMA Thrombin Receptor Antagonists
Aug, 2015

(7 years ago)

CN1436185A XSPIRE PHARMA Thrombin Receptor Antagonists
Aug, 2015

(7 years ago)

CN1659162A XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

CN1659162B XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

CN1910176B XSPIRE PHARMA Crystalline Polymorph Of A Bisulfate Of A Thrombin Receptor Antagonist
Sep, 2024

(1 year, 11 months from now)

CN1910176A XSPIRE PHARMA Crystalline Polymorph Of A Bislulfate Salt Of A Thrombin Receptor Antagonist
Sep, 2024

(1 year, 11 months from now)

CN101899039B XSPIRE PHARMA Crystalline Polymorph Of A Bisulfate Of A Thrombin Receptor Antagonist
Sep, 2024

(1 year, 11 months from now)

CN101899039A XSPIRE PHARMA Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
Sep, 2024

(1 year, 11 months from now)

IN200402291P4 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists Of Formula I
Apr, 2023

(6 months from now)

IN218783B XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists Of Formula I
Apr, 2023

(6 months from now)

EP2301930A1 XSPIRE PHARMA Derivatives Of Hexahydrobenzofuranone Useful For The Treatment Of (Inter Alia) Auto-Immune Or Inflammatory Disorders
Jun, 2021

(1 year, 3 months ago)

EP2301930B1 XSPIRE PHARMA Derivatives Of Hexahydrobenzofuranone Useful For The Treatment Of (Inter Alia) Auto-Immune Or Inflammatory Disorders
Jun, 2021

(1 year, 3 months ago)

EP1294714B1 XSPIRE PHARMA Thrombin Receptor Antagonists
Jun, 2021

(1 year, 3 months ago)

EP1294714A2 XSPIRE PHARMA Thrombin Receptor Antagonists
Jun, 2021

(1 year, 3 months ago)

EP1982984B1 XSPIRE PHARMA Manufacture Of Tricyclic Thrombin Receptor Antagonists And Pharmaceutical Compositions Comprising Them
Apr, 2023

(6 months from now)

EP1982984A2 XSPIRE PHARMA Manufacture Of Tricyclic Thrombin Receptor Antagonists And Pharmaceutical Compositions Comprising Them
Apr, 2023

(6 months from now)

EP2062890B1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonist
Apr, 2023

(6 months from now)

EP1982984A3 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP1860106B1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP2065384A1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonist
Apr, 2023

(6 months from now)

EP2062890A1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonist
Apr, 2023

(6 months from now)

EP1860106A1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP2065384B1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonist
Apr, 2023

(6 months from now)

EP1495018B1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP1495018B3 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP1495018A1 XSPIRE PHARMA Tricyclic Thrombin Receptor Antagonists
Apr, 2023

(6 months from now)

EP1663965A2 XSPIRE PHARMA Thrombin Receptor Antagonists
Sep, 2024

(1 year, 11 months from now)

EP1663965B1 XSPIRE PHARMA Thrombin Receptor Antagonists
Sep, 2024

(1 year, 11 months from now)

EP2277879A1 XSPIRE PHARMA Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
Jan, 2025

(2 years from now)

EP2277879B1 XSPIRE PHARMA Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
Jan, 2025

(2 years from now)

EP1701953A1 XSPIRE PHARMA Process For The Production Of A Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
Jan, 2025

(2 years from now)

EP1701953B1 XSPIRE PHARMA Process For The Production Of A Crystalline Polymorph Of A Bisulfate Salt Of A Thrombin Receptor Antagonist
Jan, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.08MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.